Showing 3361-3370 of 6035 results for "".
- Valitor Presents Preclinical Safety Data on Long-Acting Anti-VEGF VLTR-559 for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-safety-data-on-long-acting-anti-vegf-vltr-559-for-wet-amd/2484137/Valitor announced new preclinical data on VLTR-559, its long-acting anti-VEGF biologic in development for wet age-related macular degeneration (AMD). The findings were featured in a presentation at the Ophthalmology Futures Retina Forum.
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr
- VSY Biotechnology Launches Enova Hydrophobic IOLs with Rotaryjet Technologyhttps://modernod.com/news/vsy-biotechnology-launches-enova-hydrophobic-iols-with-rotaryjet-technology/2482932/VSY Biotechnology has launched the Enova Hydrophobic IOLs, with the company's Rotaryjet Preloaded Delivery System. This technology is designed to provide ophthalmic surgeons with a safer, more efficient, and user-friendly solution for lens implantation. The patented Rotary
- OKYO Pharma Secures Funding to Advance Urcosimod for Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-secures-funding-to-advance-urcosimod-for-neuropathic-corneal-pain/2482926/OKYO Pharma announced it has received $1.9 million in non-dilutive funding to accelerate the clinical development of urcosimod, the company’s lead candidate for treating Neuropathic Corneal Pain (NCP) “Neur
- Mark Maire Appointed CEO of Rebionhttps://modernod.com/news/mark-maire-appointed-ceo-of-rebion/2482920/Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer. Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVi
- Alcon to Acquire Staar Surgical for $1.5 Billionhttps://modernod.com/news/alcon-to-acquire-staar-surgical-for-15-billion/2482917/In a major deal to expand its refractive portfolio and continue its spree of acquisitions, Alcon has agreed to acquire Staar Surgical, maker of the Implantable Collamer Lens (ICL). The acquisition includes the EVO family of l
- Topcon Partners with OKKO Health to Advance Home-Based Vision Monitoring and Patient Engagementhttps://modernod.com/news/topcon-partners-with-okko-health-to-advance-home-based-vision-monitoring-and-patient-engagement/2482894/Topcon Healthcare announced an investment in OKKO Health, a UK-based provider of vision testing software. While financial terms of the deal were not disclosed, the investment positions Topcon as the lead in OKKO Health’s seed funding round.
- Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space Delivery Platformhttps://modernod.com/news/clearside-biomedical-announces-plan-to-explore-strategic-alternatives-to-advance-its-proprietary-suprachoroidal-space-delivery-platform/2482892/Clearside Biomedical announced it has initiated a formal process to explore a range of strategic alternatives aimed at maximizing shareholder value and advancing its pipeline. To support this initiative, Clearside has
- Stuart Therapeutics Publishes New Study Demonstrating Potential of Collagen Mimetic Peptides in Treating Ophthalmic Diseasehttps://modernod.com/news/stuart-therapeutics-publishes-new-study-demonstrating-potential-of-collagen-mimetic-peptides-in-treating-ophthalmic-disease/2482887/Stuart Therapeutics announced the publication of a preclinical study in Pharmaceuticals highlighting the potential of collagen mimetic peptides (CMPs) in restor
- Alcon Receives Health Canada Approval for Unity VCShttps://modernod.com/news/alcons-receives-health-canada-approval-for-unity-vcs/2482882/Alcon announced that Unity Vitreoretinal Cataract System (VCS) has received Health Canada approval. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon’s current leading systems, Constellation Vision System for vitreoretinal and combined proce